1
|
Wang XM, Holz LE, Chowdhury S, Cordoba SP, Evans KA, Gall MG, Vieira de Ribeiro AJ, Zheng YZ, Levy MT, Yu DM, Yao TW, Polak N, Jolly CJ, Bertolino P, McCaughan GW, Gorrell MD. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. Immunol Cell Biol 2016; 95:443-453. [PMID: 27899813 DOI: 10.1038/icb.2016.116] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2016] [Revised: 11/04/2016] [Accepted: 11/24/2016] [Indexed: 12/19/2022]
Abstract
Liver fibrosis is a progressive pathological process involving inflammation and extracellular matrix deposition. Dipeptidyl peptidase 4 (DPP4), also known as CD26, is a cell surface glycoprotein and serine protease. DPP4 binds to fibronectin, can inactivate specific chemokines, incretin hormone and neuropeptides, and influences cell adhesion and migration. Such properties suggest a pro-fibrotic role for this peptidase but this hypothesis needs in vivo examination. Experimental liver injury was induced with carbon tetrachloride (CCl4) in DPP4 gene knockout (gko) mice. DPP4 gko had less liver fibrosis and inflammation and fewer B cell clusters than wild type mice in the fibrosis model. DPP4 inhibitor-treated mice also developed less liver fibrosis. DNA microarray and PCR showed that many immunoglobulin (Ig) genes and some metabolism-associated transcripts were differentially expressed in the gko strain compared with wild type. CCl4-treated DPP4 gko livers had more IgM+ and IgG+ intrahepatic lymphocytes, and fewer CD4+, IgD+ and CD21+ intrahepatic lymphocytes. These data suggest that DPP4 is pro-fibrotic in CCl4-induced liver fibrosis and that the mechanisms of DPP4 pro-fibrotic action include energy metabolism, B cells, NK cells and CD4+ cells.
Collapse
Affiliation(s)
- Xin M Wang
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - Lauren E Holz
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Sumaiya Chowdhury
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Shaun P Cordoba
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Kathryn A Evans
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Margaret G Gall
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | | | - Yuan Zhou Zheng
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Miriam T Levy
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - Denise Mt Yu
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Tsun-Wen Yao
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Natasa Polak
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Christopher J Jolly
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Patrick Bertolino
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Geoffrey W McCaughan
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - Mark D Gorrell
- Centenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| |
Collapse
|
2
|
Cordoba SP, Wang C, Williams R, Li J, Smit L, Sharland A, Allen R, McCaughan G, Bishop A. Gene array analysis of a rat model of liver transplant tolerance identifies increased complement C3 and the STAT-1/IRF-1 pathway during tolerance induction. Liver Transpl 2006; 12:636-43. [PMID: 16555329 DOI: 10.1002/lt.20637] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
This study aimed to define the molecular mechanism during induction of spontaneous liver transplant tolerance using microarrays and to focus on molecular pathways associated with tolerance by meta-analysis with published studies. The differences in the early immune response between PVG to DA liver transplant recipients that are spontaneously tolerant (TOL) and PVG to Lewis liver transplants that reject (REJ) were examined. Spleens from TOL and REJ on days 1 and 3 were compared by 2 color microarray. Forty-six of 199 genes differentially expressed between TOL and REJ had an immunological function. More immune genes were increased in TOL vs. REJ on day 1, including STAT-1, IRF-1 and complement C3. Differential expression of selected genes was confirmed by quantitative RT-PCR. The results were compared to two published high-throughput studies of rat liver transplant tolerance and showed that C3 was increased in all three models, while STAT-1 and IRF-1 were increased in two models. The early increases in immune genes in TOL confirmed previous reports of an active early immune response in TOL. In conclusion, the increase in STAT-1, IRF-1 and complement component C3 in several models of liver transplant tolerance suggests that the STAT-1/IRF-1 apoptotic pathway and C3 may be involved in the tolerogenic mechanism.
Collapse
Affiliation(s)
- Shaun P Cordoba
- AW Morrow Liver Immunobiology Laboratory, Centenary Institute, UNSW Sydney, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Wang C, Li J, Cordoba SP, McLeod DJ, Tran GT, Hodgkinson SJ, Hall BM, McCaughan GW, Bishop GA. Posttransplant Interleukin-4 Treatment Converts Rat Liver Allograft Tolerance to Rejection. Transplantation 2005; 79:1116-20. [PMID: 15880053 DOI: 10.1097/01.tp.0000161249.20922.16] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Previous studies showed that liver transplant rejection in the Piebald Virol Glaxo (PVG)-to-Lewis combination was associated with more intragraft interleukin (IL)-4 mRNA expression than in spontaneously tolerant grafts in the PVG-to-Dark Agouti (DA) combination. There was also immunoglobulin (Ig) G1 antibody deposition, suggesting an IL-4-induced IgG class switch in rejection. The aim of this study was to investigate whether IL-4 treatment converts PVG-->DA liver transplant tolerance to rejection. METHODS DA (RT1a) rats were recipients of orthotopic PVG (RT1c) liver transplants and DA liver transplants were syngeneic controls. Supernatant from IL-4-transfected Chinese hamster ovary cells (0.5 mL, 30,000 U) or from untransfected cells was injected intraperitoneally on days 3 through 7. Samples were taken for immunohistochemical staining of frozen tissue sections to analyze cellular infiltrate and antibody deposition. RESULTS IL-4 treatment significantly reduced survival of liver allografts from greater than 100 days in untreated animals to 9 days (P=0.004). Pathologic analysis of IL-4-treated animals showed that death was caused by liver transplant rejection, with a heavy infiltrate of mononuclear cells, disruption of portal tract areas, and infarction. Immunohistochemistry revealed an extensive infiltrate of T cells, CD25-expressing cells, and B cells that was similar to the level in PVG--> Lewis liver allograft recipients that reject the liver. There was also a more extensive monocyte-macrophage infiltrate and more major histocompatibility complex class II expression in IL-4-treated animals compared with untreated animals. There was moderate increase of IgM, little IgG1, and no IgE or IgG2a antibody deposition. CONCLUSIONS IL-4, a T-helper type 2 cytokine that has previously been shown to inhibit delayed-type hypersensitivity responses such as rejection, was found to promote rejection of liver allografts. There was only slight evidence of a graft-specific antibody response, showing that IL-4 induces liver allograft rejection in association with some, but not all, of the changes accompanying rejection in the PVG-->Lewis strain combination.
Collapse
Affiliation(s)
- Chuanmin Wang
- Liver Laboratory, Centenary Institute, Sydney University, Camperdown, NSW, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|